Literature DB >> 12538805

The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine.

Ai-Ming Yu1, Camille P Granvil, Robert L Haining, Kristopher W Krausz, Javier Corchero, Adrian Küpfer, Jeffrey R Idle, Frank J Gonzalez.   

Abstract

Tryptamine is a trace amine in mammalian central nervous system that interacts with the trace amine TA(2) receptor and is now thought to function as a neurotransmitter or neuromodulator. It had been reported that deamination of tryptamine to tryptophol was mediated by CYP2D6, a cytochrome P450 that is expressed in human brain, suggesting that tryptamine may be an endogenous substrate for this polymorphic enzyme. We were unable to confirm this report and have reinvestigated tryptamine metabolism in human liver microsomes (HLM) and in microsomes expressing recombinant human cytochrome P450 and monoamine oxidase (MAO) isozymes. Tryptamine was oxidized to indole-3-acetaldehyde by HLM and recombinant human MAO-A in the absence of NADPH, and indole-3-acetaldehyde was further reduced to tryptophol by aldehyde reductase in HLM in the presence of NADPH. Steady-state kinetic parameters were estimated for each reaction step by HLM and MAO-A. The CYP2D6 substrates bufuralol and debrisoquine showed strong inhibition of both tryptophol production from tryptamine in HLM and the formation of indole-3-acetaldehyde from tryptamine catalyzed by recombinant MAO-A. Anti-CYP2D6 monoclonal antibody did not inhibit these reactions. Pargyline, a nonselective MAO inhibitor, did not show cross inhibition to debrisoquine 4-hydroxylation and dextromethorphan O-demethylation by HLM and recombinant CYP2D6 enzyme. This is the first unequivocal report of the selective conversion of tryptamine to tryptophol by MAO-A. CYP2D6 does not contribute to this reaction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12538805     DOI: 10.1124/jpet.102.043786

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

Review 1.  Trace amine-associated receptors and their ligands.

Authors:  R Zucchi; G Chiellini; T S Scanlan; D K Grandy
Journal:  Br J Pharmacol       Date:  2006-11-06       Impact factor: 8.739

2.  Ethanol self-administration and nicotine treatment increase brain levels of CYP2D in African green monkeys.

Authors:  R T Miller; S Miksys; E Hoffmann; R F Tyndale
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

3.  Utilization of Liver Microsomes to Estimate Hepatic Intrinsic Clearance of Monoamine Oxidase Substrate Drugs in Humans.

Authors:  Yusuke Masuo; Shushi Nagamori; Aoi Hasegawa; Kazuki Hayashi; Noriyoshi Isozumi; Noritaka Nakamichi; Yoshikatsu Kanai; Yukio Kato
Journal:  Pharm Res       Date:  2017-03-30       Impact factor: 4.200

4.  3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.

Authors:  Yueying Zhen; Ondrej Slanar; Kristopher W Krausz; Chi Chen; Josef Slavík; Kerry L McPhail; T Mark Zabriskie; Frantisek Perlík; Frank J Gonzalez; Jeffrey R Idle
Journal:  Drug Metab Dispos       Date:  2006-06-16       Impact factor: 3.922

5.  Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.

Authors:  Hong-Wu Shen; Chao Wu; Xi-Ling Jiang; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2010-03-03       Impact factor: 5.858

Review 6.  Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models.

Authors:  Xi-Ling Jiang; Frank J Gonzalez; Ai-Ming Yu
Journal:  Drug Metab Rev       Date:  2010-09-21       Impact factor: 4.518

7.  Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice.

Authors:  Hong-Wu Shen; Xi-Ling Jiang; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2011-04-04       Impact factor: 3.922

Review 8.  Indolealkylamines: biotransformations and potential drug-drug interactions.

Authors:  Ai-Ming Yu
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

Review 9.  Trace amine-associated receptor 1-Family archetype or iconoclast?

Authors:  David K Grandy
Journal:  Pharmacol Ther       Date:  2007-07-17       Impact factor: 12.310

Review 10.  Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds.

Authors:  Guillermo Gervasini; Juan Antonio Carrillo; Julio Benitez
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.